Loading...

IMRX IMMUNEERING CORP Management Changes 8-K Filing

MMNR

MRX

IMMUNEERING CORP

(IMRX)

2024 8-K

Show Summary

Summary

Clinical Trials

Financial Statements

Financial Results

Clinical Trial Update

Clinical Trial Update

Financial Results

Director Appointment

Clinical Trial Update

Financial Results Announcement

Annual Meeting of Stockholders

Repricing of Options

Appointment of Director

Financial Results Announcement

Amendments to Bylaws

Financial Results Announcement

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

Public Offering

Results of Operations and F...

Financial Results Announcement

External Links:

Immuneering Corp appointed Thomas J. Schall, Ph.D. as a member of their Board of Directors and announced the dosing of the first patient in their Phase 2a clinical trial of IMM-1-104 in advanced RAS-mutant solid tumors.

AI Assistant

IMMUNEERING CORP

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.